Investment bank Leerink Partners announced the initiation of research coverage on biotechnology company AgomAb Therapeutics (AGMB), assigning an "Outperform" rating.
Show original
The institution has set a target stock price of $36 for the company, demonstrating a positive outlook on its future growth potential. This coverage marks an increased market focus on AgomAb Therapeutics' R&D pipeline. Leerink Partners' optimistic rating is based on an in-depth assessment of the company's core technology and business prospects.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
The Baltic Dry Index continues its upward trend
金十•2026/03/03 14:39
The Baltic Dry Index continues its upward trend
金十•2026/03/03 14:37
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$66,476.16
-0.08%
Ethereum
ETH
$1,944.19
-1.24%
Tether USDt
USDT
$0.9998
+0.00%
BNB
BNB
$622.56
-0.78%
XRP
XRP
$1.34
-1.53%
USDC
USDC
$1.0000
+0.00%
Solana
SOL
$83.13
-1.83%
TRON
TRX
$0.2803
-0.54%
Dogecoin
DOGE
$0.08924
-3.99%
Cardano
ADA
$0.2628
-4.50%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now